Pathogen Acquisition in Patients with Cystic Fibrosis Receiving Ivacaftor or Lumacaftor/Ivacaftor

BACKGROUND: The CFTR modulators ivacaftor and lumacaftor/ivacaftor improve the status of existing infections in patients with cystic fibrosis (CF). It is unknown how well these drugs protect patients against incident infections. We hypothesized that CFTR modulator treatment would decrease new infect...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatr Pulmonol
Hauptverfasser: Singh, Sachinkumar B., McLearn-Montz, Amanda J., Milavetz, Francesca, Gates, Levi K., Fox, Christopher, Murry, Logan T., Sabus, Ashley, Porterfield, Harry S., Fischer, Anthony J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6641998/
https://ncbi.nlm.nih.gov/pubmed/31012285
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ppul.24341
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge